Incyte CEO Named to Aurora Biosciences Board | GenomeWeb

LA JOLLA, Calif.--Roy Whitfield, CEO of genomics and bioinformatics company Incyte Pharmaceuti cals, has joined the board of directors of Aurora Biosciences, a company here that designs and develops proprietary drug discovery systems, services, and technologies. Aurora's current collaborators include Bristol-Myers Squibb, Eli Lilly, Roche Bioscience, Sequana Therapeutics, and Allelix Bio pharmaceuticals.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.